OBJECTIVES: To compare lipid profiles in patients with rheumatoid arthritis (RA) and in non-RA subjects during the 5 years before and 5 years after the RA incidence/index date. METHODS: Lipid measures were abstracted in a population-based incident cohort of patients with RA (1987 American College of Rheumatology criteria) first diagnosed between 1 January 1988 and 1 January 2008 and in non-RA subjects. Random-effects models adjusting for age, sex and calendar year were used to examine trends in lipid profiles, accounting for multiple measurements for each subject. RESULTS: The study population included a cohort of 577 patients with RA (a total of 3088 lipid measurements) and 540 non-RA subjects (a total of 3048 lipid measurements). There were significant decreases in total (TC) and low-density lipoprotein cholesterol (LDL) levels in the RA cohort during the 5 years before RA, compared with the non-RA cohort (p<0.001). Decreases of 0.58 mmol/l for TC and 0.61 mmol/l for LDL were noted in RA compared with decreases of 0.09 mmol/l for TC and 0.22 mmol/l for LDL in the non-RA cohort. Trends in other lipid measures (triglycerides (TGs) and high-density lipoprotein cholesterol (HDL)) were similar in RA and non-RA cohorts during the 5 years before and 5 years after the RA incidence/index date. During the 5 years before the RA incidence/index date, the proportion of patients with RA with elevated TC or LDL measures, but not with abnormal HDL and TG measures, significantly decreased compared with non-RA subjects. Lipid-lowering drugs (statins in particular) were less often prescribed to patients with RA than to non-RA subjects (34% vs 41%; p=0.02). CONCLUSION: TC and LDL levels and the prevalence of abnormal TC or LDL measures decreased significantly during the 5 years before the RA incidence/index date in patients with RA as compared with the non-RA cohort. These trends in lipid profile in RA are unlikely to be solely due to lipid-lowering treatment.
OBJECTIVES: To compare lipid profiles in patients with rheumatoid arthritis (RA) and in non-RA subjects during the 5 years before and 5 years after the RA incidence/index date. METHODS:Lipid measures were abstracted in a population-based incident cohort of patients with RA (1987 American College of Rheumatology criteria) first diagnosed between 1 January 1988 and 1 January 2008 and in non-RA subjects. Random-effects models adjusting for age, sex and calendar year were used to examine trends in lipid profiles, accounting for multiple measurements for each subject. RESULTS: The study population included a cohort of 577 patients with RA (a total of 3088 lipid measurements) and 540 non-RA subjects (a total of 3048 lipid measurements). There were significant decreases in total (TC) and low-density lipoprotein cholesterol (LDL) levels in the RA cohort during the 5 years before RA, compared with the non-RA cohort (p<0.001). Decreases of 0.58 mmol/l for TC and 0.61 mmol/l for LDL were noted in RA compared with decreases of 0.09 mmol/l for TC and 0.22 mmol/l for LDL in the non-RA cohort. Trends in other lipid measures (triglycerides (TGs) and high-density lipoprotein cholesterol (HDL)) were similar in RA and non-RA cohorts during the 5 years before and 5 years after the RA incidence/index date. During the 5 years before the RA incidence/index date, the proportion of patients with RA with elevated TC or LDL measures, but not with abnormal HDL and TG measures, significantly decreased compared with non-RA subjects. Lipid-lowering drugs (statins in particular) were less often prescribed to patients with RA than to non-RA subjects (34% vs 41%; p=0.02). CONCLUSION:TC and LDL levels and the prevalence of abnormal TC or LDL measures decreased significantly during the 5 years before the RA incidence/index date in patients with RA as compared with the non-RA cohort. These trends in lipid profile in RA are unlikely to be solely due to lipid-lowering treatment.
Authors: Clementien L Vermont; Marieke den Brinker; Nimet Kâkeci; Ester D de Kleijn; Yolanda B de Rijke; Koen F M Joosten; Ronald de Groot; Jan A Hazelzet Journal: Crit Care Med Date: 2005-07 Impact factor: 7.598
Authors: Margaret D Carroll; David A Lacher; Paul D Sorlie; James I Cleeman; David J Gordon; Michael Wolz; Scott M Grundy; Clifford L Johnson Journal: JAMA Date: 2005-10-12 Impact factor: 56.272
Authors: Hilal Maradit-Kremers; Cynthia S Crowson; Paulo J Nicola; Karla V Ballman; Véronique L Roger; Steve J Jacobsen; Sherine E Gabriel Journal: Arthritis Rheum Date: 2005-02
Authors: D Jacobs; H Blackburn; M Higgins; D Reed; H Iso; G McMillan; J Neaton; J Nelson; J Potter; B Rifkind Journal: Circulation Date: 1992-09 Impact factor: 29.690
Authors: György Kerekes; Michael T Nurmohamed; Miguel A González-Gay; Ildikó Seres; György Paragh; Zsófia Kardos; Zsuzsa Baráth; László Tamási; Pál Soltész; Zoltán Szekanecz Journal: Nat Rev Rheumatol Date: 2014-08-05 Impact factor: 20.543
Authors: Katherine P Liao; Dorothée Diogo; Jing Cui; Tianxi Cai; Yukinori Okada; Vivian S Gainer; Shawn N Murphy; Namrata Gupta; Daniel Mirel; Ashwin N Ananthakrishnan; Peter Szolovits; Stanley Y Shaw; Soumya Raychaudhuri; Susanne Churchill; Isaac Kohane; Elizabeth W Karlson; Robert M Plenge Journal: Ann Rheum Dis Date: 2013-05-28 Impact factor: 19.103